Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment-Reference-Cited by-同舟云学术

Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment

Published:2022-07-07 Issue:9 Volume:39 Page:4114-4130
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Shubrook Jay H.,Radin Michael,Ali Sarah N.,Chubb Barrie,DiPietrantonio Kristina,Collings Hannah^ORCID,Wyn Robin,Smith Martina

Funder

Novo Nordisk

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02181-7.pdf

Reference39 articles.

1. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S13–27.

2. Ali SN, Dang-Tan T, Valentine WJ, Hansen BB. Evaluation of the clinical and economic burden of poor glycemic control associated with therapeutic inertia in patients with type 2 diabetes in the United States. Adv Ther. 2020;37(2):869–82.

3. Centers for Disease Control and Prevenetion. National Diabetes Statistics Report 2020: estimates of diabetes and its burden in the United States. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statisticsreport.pdf. Accessed 5 July 2022.

4. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S73–85.

5. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. 2020;46:101102.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preference for a Novel Oral Alternative to Parenterally Administered Medications;Patient Preference and Adherence;2024-07

2. Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?;Journal of Endocrinological Investigation;2024-04-29

3. Use of once‐daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: A multicentre, prospective real‐world study (PIONEER REAL Canada);Diabetes, Obesity and Metabolism;2024-03-11

4. Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study;Clinical Diabetes;2024-01-22

5. Evaluating Preferences of Hospitalized Diabetes Patients for Hospital‐Wide Glycemic Control Programme: A Discrete Choice Experiment;Journal of Diabetes Research;2024-01